A–Z of Treating Patients with ECP – The Nordic Approach Operating Room Course

The Goal

The goal of the practical course is to share the experience on how to successfully set up a new ECP centre and to optimise patient management. The interactive setting fosters discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 28 October 2024

Arrival of participants

20.00 – 20.15
Meeting at hotel lobby

20.15
Dinner with the faculty

Day 2 - 29 October 2024

09.00 – 10.00
Visit to treatment area - All

10.15 - 10.45
Department and ECP set-up - Jørn Kristiansen, Nurse

11.00 – 11.15
Group discussion

11.15 – 11.30
Coffee break

11.30 – 12.00
ECP in acute and chronic GvHD – the Oslo experience - Alf Johnson

12.00 - 12.30
Patient Focus and Nordic ECP Guidelines - Alba Pons

12.30 - 13.00
ECP in acute and chronic GvHD – Oslo experience - Alba Pons

13.00 – 14.00
Lunch

14.00 - 15.00
Vascular Access - Daniel Wergeland

15.00 – 15.45
Nurses role in ECP treatment - ECP Operator, Oslo

15.45 - 16.15
Managing patients - A cross-departmental approach - Daniel Wergeland

16.15 – 16.30
Group discussion

16.30 – 16.45
Final remarks and close - Daniel Wergeland

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals
This information is not intended for healthcare professionals based in the US and Canada.

Hosted by

Daniel Wergeland

Nurse Pratictioner, ECP Coordinator, Oslo University Hospital, Rikshospitalet

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Explore related courses

Mar 12 - 13, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

Mar 25 - 26, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

May 8 - 9, 2025

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

Jun 26 - 27, 2025

THERAKOS™ CELLEX™ Photopheresis System Interactive Workshop on Blood Prime

The Tirol Kliniken, Innsbruck, Austria

Find out more

Sep 24 - 25, 2025

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

University of Leipzig Medical Center, Leipzig, Germany

Find out more

Sep 25 - 26, 2025

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

Oct 27 - 28, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

Nov 20 - 21, 2025

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

A–Z of Treating Patients with ECP – The Nordic Approach Operating Room Course

The Goal

Agenda

Day 1 - 28 October 2024

Day 2 - 29 October 2024

Hosted by

Brought to you by the Therakos Institute

Explore related courses

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

THERAKOS™ CELLEX™ Photopheresis System Interactive Workshop on Blood Prime

The Benefits of CELLEX™ Technology - Advancing Knowledge on ECP Technology

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

Sign in to register your interest

Register your interest in attending